SEARCH

SEARCH BY CITATION

References

  • 1
    Heit JA, O'Fallon WM, Petterson TM, Lohse CM, Silverstein MD, Mohr DN, Melton LJ 3rd. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 2002; 162: 12458.DOI: 10.1001/archinte.162.11.1245
  • 2
    Cushman M, Tsai AW, Heckbert SR, White RH, Rosamond WD, Enright P, Folsom AR. Deep vein thrombosis and pulmonary embolism in two cohorts. the Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Med 2004; 117: 1925.
  • 3
    Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989; 82: 2035.
  • 4
    Baglin TP, White K, Charles A. Fatal pulmonary embolism in hospitalised medical patients. J Clin Pathol 1997; 50: 60910.
  • 5
    Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D, Decousus H. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83: 149.
  • 6
    Bergmann JF, Elkharrat D. Prevention of venous thromboembolic risk in non-surgical patients. Haemostasis 1996; 26 (Suppl. 2): 1623.
  • 7
    Bergmann JF, Mouly S. Thromboprophylaxis in medical patients: focus on France. Semin Thromb Hemost 2002; 28 (Suppl. 3): 515.
  • 8
    Bick RL. Proficient and cost-effective approaches for the prevention and treatment of venous thrombosis and thromboembolism. Drugs 2000; 60: 57595.
  • 9
    Cohen AT, Zaw HM, Alikhan R. Benefits of deep-vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX Trial. Semin Hematol 2001; 38 (2 Suppl. 5): 318.
  • 10
    Davidson BL. Risk assessment and prophylaxis of venous thromboembolism in acutely and/or critically ill patients. Haemostasis 2000; 30 (Suppl. 2): 7781.DOI: 10.1159/000054168
  • 11
    Gallus AS, Nurmohammed M, Kearon C, Prins M. Thromboprophylaxis in non-surgical patients: who, when and how? Haemostasis 1998; 28 (Suppl. 3): 7182.DOI: 10.1159/000022408
  • 12
    Haas SK. Venous thromboembolic risk and its prevention in hospitalized medical patients. Semin Thromb Hemost 2002; 28: 57784.DOI: 10.1055/s-2002-36702
  • 13
    Haas S. Risk of deep venous thrombosis in medical patients. Curr Hematol Rep 2002; 1: 856.
  • 14
    Jacobs LG. Prophylactic anticoagulation for venous thromboembolic disease in geriatric patients. J Am Geriatr Soc 2003; 51: 14728.DOI: 10.1046/j.1532-5415.2003.51469.x
  • 15
    Michota FA. Venous thromboembolism prophylaxis in the medically ill patient. Clin Chest Med 2003; 24: 93101.
  • 16
    Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Br Med J 1992; 305: 56774.
  • 17
    Arcelus JI, Candocia S, Traverso CI, Fabrega F, Caprini JA, Hasty JH. Venous thromboembolism prophylaxis and risk assessment in medical patients. Semin Thromb Hemost 1991; 17 (Suppl. 3): 3138.
  • 18
    Lutz L. Venous thromboembolism in internal medicine: risk assessment and pharmaceutical prophylaxis. Die Med Welt 2002; 53: 2314.
  • 19
    White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107 (23 Suppl. 1): I48.
  • 20
    Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793800.DOI: 10.1056/NEJM199909093411103
  • 21
    Cushman M, Folsom AR, Wang L, Aleksic N, Rosamond WD, Tracy RP, Heckbert SR. Fibrin fragment D-dimer and the risk of future venous thrombosis. Blood 2003; 101: 12438.
  • 22
    Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 1992; 152: 16604.DOI: 10.1001/archinte.152.8.1660
  • 23
    Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, Folsom AR. Coagulation factors, inflammation markers, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Med 2002; 113: 63642.DOI: 10.1016/S0002-9343(02)01345-1
  • 24
    Kroegel C, Reissig A. Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis. Respiration 2003; 70: 730.DOI: 10.1159/000068427
  • 25
    Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler M, Segestraa JM. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 1986; 16: 15964.
  • 26
    Sherry S. Interrelationships between platelets and coagulation in the pathogenesis of venous thrombosis. S Afr Med J 1976; 50: 4257.
  • 27
    Daniel S, O'Brien JR, John JA. Platelets in the prediction of thrombotic risk. Atherosclerosis 1982; 45: 919.
  • 28
    Lowe GD. Prediction of postoperative venous thrombosis using haemostasis tests. Int J Clin Lab Res 1997; 27: 1537.
  • 29
    Phillips AN, Smith GD. How independent are ‘independent’ effects? Relative risk estimation when correlated exposures are measured imprecisely. J Clin Epidemiol 1991; 44: 122331.DOI: 10.1016/0895-4356(91)90155-3